Skip to main content
Signal8
Launch Terminal

Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Dermata Therapeutics, Inc. logo

Dermata Therapeutics, Inc.

NASDAQ:DRMAHealthcare
-7.86%$0.7750
AH$0.7899+1.92%vs close
Mkt Cap$3.84M
Float3.02M
O/S4.96M
Vol
$ Vol
RVOL
Inst Own2.4%
SI2.6%
Earnings
Dilution
Dermata Therapeutics, Inc. logoNASDAQ:DRMA$0.7750-7.86%
FormDescription
8-K
8.01
2
424B3
Prospectus
7
EFFECT
Notice of Effectiveness
1
S-3
Shelf Registration Statement
7
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
25-NSE
SEC Filing
3
8-K
1.01,3.02,8.01,9.01
6
10-Q
Quarterly Report
8
8-K
2.02,9.01
5
8-K
8.01
4
4
Statement of Changes in Beneficial Ownership
S-8
SEC Filing
13D
Beneficial Ownership Report (Active)
EFFECT
Notice of Effectiveness
424B3
Prospectus
5
8-K
5.02,5.07,9.01
3
CORRESP
SEC Filing
S-3/A
Shelf Registration Statement (Amended)
4
13G/A
Beneficial Ownership Report (Amended)
10-Q
Quarterly Report
3
8-K
2.02,9.01
13G/A
Beneficial Ownership Report (Amended)
ARS
SEC Filing
DEFA14A
Additional Proxy Materials

1-25 of 370

…

Recent SEC filings with analysis

    Dermata Therapeutics, Inc. (DRMA) SEC Filings: 10-K, 10-Q, 8-K, Form 4 | Signal8